Education
About Us
Working with TipRanks
Follow Us
Mdxhealth S.A. (MDXH)
NASDAQ:MDXH
MDXH Stock Chart & Stats
$3.20
-$0.10(-4.55%)
At close: 4:00 PM EST
$3.20
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$1.36 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)106.61K
Market Cap
$158.39M
Enterprise Value$230.45M
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 14, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding49,497,334
10 Day Avg. Volume118,163
30 Day Avg. Volume106,614
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue2.14
Enterprise Value/Gross Profit3.58
Enterprise Value/Ebitda-37.21
Forecast
1Y Price Target
$7.67Price Target Upside139.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$137.80M
Bulls Say, Bears Say
Bulls Say
Clinical StudiesAnalyst expects ongoing clinical studies for the GPS test to produce results that could increase guideline support and drive broader clinical adoption of the test.
Revenue Guidance MomentumCompany-issued revenue guidance above consensus combined with results that beat expectations suggests commercial momentum that could support upside for the shares.
Test Volume GrowthReported increases in both tissue and liquid test volumes and strong demand for the Resolve UTI test point to expanding market acceptance and multiple sources of revenue growth.
Bears Say
Acquisition-related Integration RiskTiming and integration issues tied to the acquisition caused a revenue shortfall versus preliminary expectations, indicating potential disruption to top-line growth.
Product Reprioritization And Sales ExecutionDeprioritizing select products led to a sales shortfall versus expectations, underscoring execution risk from shifts in product focus.
Profitability Pressure From Higher CostsHigher headcount and acquisition-related expenses weighed on adjusted EBITDA, highlighting the risk that elevated operating costs could pressure profitability.
MDxHealth News
MDXH FAQ
What was Mdxhealth S.A.’s price range in the past 12 months?
Mdxhealth S.A. lowest stock price was $1.36 and its highest was $5.33 in the past 12 months.
What is Mdxhealth S.A.’s market cap?
Mdxhealth S.A.’s market cap is $158.39M.
When is Mdxhealth S.A.’s upcoming earnings report date?
Mdxhealth S.A.’s upcoming earnings report date is May 14, 2026 which is in 61 days.
How were Mdxhealth S.A.’s earnings last quarter?
Mdxhealth S.A. released its earnings results on Feb 26, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.125 by -$0.045.
Is Mdxhealth S.A. overvalued?
According to Wall Street analysts Mdxhealth S.A.’s price is currently Undervalued.
Does Mdxhealth S.A. pay dividends?
Mdxhealth S.A. does not currently pay dividends.
What is Mdxhealth S.A.’s EPS estimate?
Mdxhealth S.A.’s EPS estimate is -0.15.
How many shares outstanding does Mdxhealth S.A. have?
Mdxhealth S.A. has 49,497,334 shares outstanding.
What happened to Mdxhealth S.A.’s price movement after its last earnings report?
Mdxhealth S.A. reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.125. Following the earnings report the stock price went down -4.225%.
Which hedge fund is a major shareholder of Mdxhealth S.A.?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (139.69% Upside)
$7.67 (139.69% Upside)
Blogger Sentiment
Bullish
MDXH Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 22.3%
Last 30 Days ▲ 22.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.33%
12-Months-Change
Fundamentals
Return on Equity
516.59%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
Mdxhealth S.A.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company in growth and transition: strong top-line and unit growth (notably a 62% unit increase and 128% rise in liquid volumes), successful integration steps with ExoDx and a clearer path to cross-selling and clinical validation, offset by near-term profitability pressure from integration costs, higher operating and financial expenses, and a modest downward adjustment to reported revenue. Management provided optimistic 2026 guidance (approx. 28% revenue growth and a target of 10% adjusted EBITDA exiting the year) and secured earnout amendment relief (~$20M), signaling confidence in returning to operating leverage despite short-term headwinds.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$7.67
▲(139.69% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.28% Mutual Funds
44.29% Other Institutional Investors
54.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---